Ulcerative Colitis News : GoldBamboo.com http://goldbamboo.com/ Ulcerative Colitis News from GoldBamboo.com en-us © 2005, Gold Bamboo LLC, All Rights Reserved FDA Approves LIALDA (mesalamine), The First Oral Once-Daily Mesalamine For Patients With Active, Mild To Moderate Ulcerative Colitis http://goldbamboo.com/news-a216622.html Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) has approved LIALDATM (mesalamine) with MMX(R) technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. LIALDA is the first and only FDA-approved once-daily oral formulation of mesalamine. [click link for full article] Mon, 22 Jan 2007 06:00 EST The Metabolic Response To Colitis Varies Depending Upon Whether Inflammation Is Chronic Or Acute http://goldbamboo.com/news-a222791.html A new study being published by the American Physiological Society (www.The-APS.org) finds that the body responds differently to colitis (inflammation of the colon) based on whether the disease is acute (sharp and brief) or chronic (long-term). [click link for full article] Mon, 26 Feb 2007 11:00 EST The Majority Of Ulcerative Colitis Patients Are Not Compliant With Medications, CCFA Survey Finds http://goldbamboo.com/news-a213546.html A new, large survey supported by the Crohn's & Colitis Foundation of America (CCFA) finds that 65 percent of ulcerative colitis (UC) patients are less than fully compliant with first-line therapies to treat their disease. The findings are significant because an earlier study found that patients less than fully compliant experience five times the number of disease flare-ups. [click link for full article] Sun, 31 Dec 2006 05:00 EST National Colorectal Cancer Awareness Month http://goldbamboo.com/news-a224220.html On March 1, 2007, the Crohn's & Colitis Foundation of America presented "Update on Colorectal Cancer: Knowledge Is Prevention," a FREE live educational teleconference for patients, caregivers, and healthcare professionals. [click link for full article] Tue, 06 Mar 2007 08:00 EST Procter & Gamble Pharmaceuticals Commemorates 15 Years Of Trusted Leadership With Asacol(R) (Mesalamine) Delayed-Release Tablets http://goldbamboo.com/news-a218700.html Procter & Gamble Pharmaceuticals, Inc. today celebrates the trusted efficacy of Asacol on its 15th anniversary. Asacol is the No. 1 most prescribed 5-ASA therapy for ulcerative colitis (UC), a form of inflammatory bowel disease (IBD).(1) More than 20 million prescriptions have been written for Asacol since it was approved by the U.S. Food and Drug Administration and launched in 1992. [click link for full article] Fri, 02 Feb 2007 08:00 EST